Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer

Whitson, Jared M; Berry, Anna B; Carroll, Peter R; Konety, Badrinath R.
Int. braz. j. urol ; 35(6): 664-672, Nov.-Dec. 2009. tab, ilus
Artículo en Inglés | LILACS | ID: lil-536799

Documentos relacionados

  1. Current best practice for bladder cancer: a narrative review of diagnostics and treatments.
  2. [Practical application of the Paris system for reporting urinary cytology].
  3. The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours.
  4. Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
  5. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
  6. Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning.
  7. Deregulated Expression of <i>IL-37</i> in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the <i>IL-37e</i> Isoform.
  8. Patterns of mutations in nine cancer-related genes and PAF development among smoking male patients diagnosed with bladder cancer.
  9. Bladder cancer: An Update.
  10. U-Net-Based Assistive Identification of Bladder Cancer: A Promising Approach for Improved Diagnosis.